Uromigos Live 2024 ADCs in UC Panel Part 3: HER2 ADCs in Bladder Cancer

At Uromigos Live 2024, a bladder cancer panel moderated by Dr. Tom Powles focused on the use of antibody drug conjugates for the treatment of bladder cancer, analyzing the response rates of various ADC treatments and their related side effects.

Dr. Powles was joined by Andrea Apolo, MD, of the National Institute of Health; Petros Grivas, MD, PhD, of the University of Washington; Shilpa Gupta, MD, of Cleveland Clinic; and Kala Sridhar, MD, of Princess Margaret Cancer Center.

In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored, including various trials on disitamab vedotin and trastuzumab deruxtecan.

Watch the fourth segment of this panel: Novel ADCs Including HER3 and Novel Nectin-4